Sign In
Buy MNKD
$3.36
-0.0700 (-2.04%)
At Close: Jun 03, 2026
MannKind (MNKD) Matches Q3 Earnings Estimates
06:41pm, Thursday, 07'th Nov 2024
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
04:02pm, Thursday, 07'th Nov 2024
Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs.
MannKind to Present at 2024 UBS Healthcare Conference
04:15pm, Tuesday, 05'th Nov 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
06:05am, Monday, 04'th Nov 2024
Met primary objective demonstrating nintedanib DPI was safe and well tolerated Participants did not experience adverse events typically reported with oral nintedanib Expect to meet with the FDA in 1H
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?
10:16am, Friday, 01'st Nov 2024
MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
04:05pm, Thursday, 31'st Oct 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease
Why MannKind (MNKD) Could Beat Earnings Estimates Again
01:15pm, Monday, 07'th Oct 2024
MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MannKind (MNKD) Just Overtook the 20-Day Moving Average
10:37am, Friday, 04'th Oct 2024
MannKind (MNKD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MNKD broke through the 20-day moving average, which suggests a short
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
08:00am, Thursday, 03'rd Oct 2024
MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 milli
More Adults With Type 1 Diabetes Achieved A1C Goal (
06:00am, Monday, 30'th Sep 2024
30-week results from the Phase 4 INHALE-3 study expand upon the positive 17-week data presented earlier this year at the American Diabetes Association's 84 th Scientific Sessions Switching to, or rema
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
04:30pm, Tuesday, 10'th Sep 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled th
MannKind to Present at Upcoming Conferences
04:30pm, Tuesday, 27'th Aug 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled the
Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board
08:00am, Wednesday, 14'th Aug 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
